The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment by Emami Nejad, A. et al.
Emami Nejad et al. Cancer Cell Int           (2021) 21:62  
https://doi.org/10.1186/s12935-020-01719-5
REVIEW
The role of hypoxia in the tumor 
microenvironment and development of cancer 
stem cell: a novel approach to developing 
treatment
Asieh Emami Nejad1, Simin Najafgholian2, Alireza Rostami3, Alireza Sistani4, Samaneh Shojaeifar5, 
Mojgan Esparvarinha6, Reza Nedaeinia7 , Shaghayegh Haghjooy Javanmard8, Marjan Taherian9, 
Mojtaba Ahmadlou10, Rasoul Salehi7,11, Bahman Sadeghi12* and Mostafa Manian13,9*
Abstract 
Hypoxia is a common feature of solid tumors, and develops because of the rapid growth of the tumor that out-
strips the oxygen supply, and impaired blood flow due to the formation of abnormal blood vessels supplying the 
tumor. It has been reported that tumor hypoxia can: activate angiogenesis, thereby enhancing invasiveness and 
risk of metastasis; increase survival of tumor, as well as suppress anti-tumor immunity and hamper the therapeutic 
response. Hypoxia mediates these effects by several potential mechanisms: altering gene expression, the activation 
of oncogenes, inactivation of suppressor genes, reducing genomic stability and clonal selection. We have reviewed 
the effects of hypoxia on tumor biology and the possible strategiesto manage the hypoxic tumor microenvironment 
(TME), highlighting the potential use of cancer stem cells in tumor treatment.
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Background
Solid tumors are the most common forms of cancer, and 
they account for high levels of morbidity and mortal-
ity globally [1]. They consist of an abnormal mass of cells 
containing blood and lymphatic vessels, components of 
the extracellular matrix (ECM), heterogeneous cells popu-
lations including fibroblasts, cancer stem cells (CSCs) and 
immune cells [2]. Solid tumors are commonly affected by 
hypoxia. In the tumor microenvironment (TME), uncon-
trolled cell proliferation often exceeds the ability to satisfy 
the oxygen demand from the preexisting blood vessels. 
This usually occurs when the tumor exceeds a diameter 
of approximately 1  mm [3, 4]. Tumor hypoxia-induced 
responses, include: altered gene expression, suppressing 
apoptosis, or promoting autophagy [5, 6], stimulation of 
the epithelial-mesenchymal transition (EMT), malignant 
progression and distant tumor metastasis [7, 8], enhanced 
angiogenesis and vasculogenesis [9–11], and changes in 
anabolic phenotype to core cellular metabolism [12, 13]. 
Moreover, hypoxia is also implicated in genomic insta-
bility due to the increased production of reactive oxygen 
species (ROS) and alterations in the DNA damage repair 
pathways [14, 15]. Hypoxia also enhances the aggressive-
ness of tumors by clonal selection. The new and more 
invasive selected clones lead to a vicious cycle of hypoxia, 
that act as a barrier to conventional cancer therapy, 
including radiotherapy, chemotherapy and phototherapy 
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[16]. Hypoxia also impacts on the immune system 
through different pathways and contributes to a reduced 
anti-tumor response [16, 17]. Furthermore, there is 
mounting evidence suggesting that CSCs that are affected 
by hypoxia are largely responsible for tumor resistance 
and recurrence after conventional therapy. In contrast, 
there is also data in the literature that suggest that hypoxia 
makes tumor cells more sensitive to chemotherapy. How-
ever, it is generally accepted that tumors that are hypoxic 
are associated with a poorer outcome. In this review, we 
describe the events in the tumor milieu that are influenced 
by hypoxia and lead to tumor expansion and malignant 
progression favoring immune escape, frustrated anti-
tumor therapy, and eventually tumor relapse, highlighting 
the function of hypoxic CSCs. Specifically, we will pursue 
the following: (i) the main transcription factors in hypoxia 
and distribution of HIF proteins in various hypoxic zones 
in tumor environment, (ii) tight regulation between 
hypoxia and angiogenesis, (iii) the role for hypoxia asso-
ciated factors in maintenance of stem-like phenotype and 
development of CSCs, (iv) the role of hypoxia in cancer 
progression, metastasis, immunosuppression, and treat-
ment resistance, (v) therapeutic strategies for re-engineer 
the hypoxic tumor microenvironment, (vi) therapeutic 
strategies considering the roles of CSCs in tumor develop-
ment, metastasis and recurrence.
Transcription factors of signaling pathways 
in hypoxia
The effects of hypoxia on tumor cells are mediated by the 
hypoxia inducible factor (HIF) family in major part [18]. 
The HIFs promote the expression of more than 150 genes, 
whose products coordinate the adaptive responses [19]. 
HIF-driven transcription encodes: vascular endothelial 
growth factor (VEGF), erythropoietin, transferrin and 
transferrin receptors, the enzymes required for glycoly-
sis, anti-apoptotic factors, multiple growth factors [such 
as platelet-derived growth factor-B (PDGF-B), trans-
forming growth factor beta (TGF-β), insulin-like growth 
factor-2 (IGF-2), epidermal growth factor (EGF)], and 
other proteins involved in normal homeostasis [20, 21]. 
Although, these factors are a part of adaptive response 
that allows them to compensate for reduced oxygen ten-
sion (and nutrients); hypoxic cancer cells overexpress 
them to increase survival, aberrant angiogenesis, extreme 
cell growth, and metastasis. The members of this fam-
ily of transcription factors; HIF1, HIF2 and HIF3, are 
heterodimers that comprise α and β subunits. HIFα is a 
cytoplasmic protein regulated by oxygen levels, whereas 
HIFβ, a nuclear protein that is constitutively expressed, 
independent of hypoxic conditions [22]. HIF1α and 
HIF2α (also called EPAS-1/HRF/HLF/MOP2) in com-
plex with HIF-1β (also known as ARNT) mediate the 
vast majority of HIF transcriptional activity. When oxy-
gen supply is sufficient, HIF1α subunit is hydroxylated 
at proline residues through oxygen-dependent enzyme 
activity. By Hydroxylation of prolyl sites binding to von 
Hippel Lindau tumor suppressor (pVHL), HIF-1α under-
goes degradation via the ubiquitin-proteasome system 
[23, 24]. Under hypoxic conditions, non-hydroxylated 
HIF-1α subunits translocated to the nucleus, where they 
combine with HIF-1β subunits to form heterodimers. 
The resultant heterodimer is the active HIF-1 factor 
binding to the hypoxia response elements of target genes 
that eventually drive the transcriptional responses [25]. 
HIF-1α appears to be expressed in most cell types, while 
the HIF-2α is mostly expressed in the endothelial cells 
(ECs) of the embryonic vasculature, neural crest-derived 
sympathetic ganglia, and of the developing pulmonary 
epithelial cells, kidney mesangial cells, and especially in 
renal cell carcinomas, in which pVHL, an E3 ligase for 
HIFα, is mutated. These two distinct, but highly related 
HIFs, have partially non-overlapping function and tar-
geting a distinct subset of hypoxia-induced genes. An 
important distinction between HIF1α and HIF2α, is the 
specific stabilization pattern under different oxygen con-
centrations. Holquimvist-Mengelbier et  al. [26], showed 
that HIF-2α, as opposed to the low HIF-1α activity, was 
strongly expressed and active at 5% oxygen (intermedi-
ate hypoxia), corresponding to well-vascularized tumor 
areas. Whereas, HIF-1α is predominantly active in 1% 
oxygen (severe hypoxia), under prolonged or chronic 
hypoxic conditions, the stabilization of HIF-1α is tran-
sient in this condition and HIF-2α is continuously accu-
mulated in prolonged, severe hypoxia (1%  O2).
Tumor hypoxia and HIF protein expression
Hypoxic zones arise as a consequence of an imbalance 
between oxygen supply and consumption in solid malig-
nant tumor, in which the oxygen pressure often reduces 
to a median of 0–20 mmHg (1%-2% or below). Whereas 
in normal healthy tissues oxygen tension is approximately 
40 mmHg (~ 5%) in the liver and approximately 100 mm 
Hg (~ 13%) in arterial blood [4, 27]. Several mechanisms 
can contribute to the development of hypoxia in the 
tumor microenvironment. Perfusion-restricted hypoxia 
(also called acute, intermittent, transient, perfusion-lim-
ited or cyclic hypoxia), that can be transient, with insuf-
ficient delivery of oxygen due to aberrant blood vessels 
undergoing repeated cycles of closing and reopening, 
and consequential sluggish blood flow and fluctuations 
in oxygen supply. These constant fluctuations lead to 
cyclic periods of hypoxia and re-oxygenation that can 
lead to the development of a heterogeneous cell popula-
tion within tumor [20, 28]. Diffusion-restricted hypoxia 
(also called chronic or permanent hypoxia) is the other 
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type of tumor hypoxia and refers to the sustained restric-
tion in oxygen diffusion by abnormal vascular network. 
Chronic hypoxia occurs when the tumor cells expand 
beyond 70 µm from the pre-existing nutritive blood ves-
sels, which prevents an adequate delivery of oxygen [29]. 
At a farther distance from the blood supply (> 180 µm), 
the tumor cells can even become necrotic [30, 31]. Occa-
sionally, anemic hypoxia can arise following a reduc-
tion in oxygen transport capacity by the blood. Anemic 
hypoxia can be either related to the presence of tumor or 
therapy-induced. Tumor tissue cannot fully compensate 
for the reduced oxygen levels, so it is more susceptible to 
anemic hypoxia [32].
Acute and chronic hypoxia are mainly mediated by 
HIF1α and HIF2α, respectively, and have often been 
reported to be associated with tumor progression and 
aggressive phenotype [26, 33]. However, as opposed 
to acute hypoxia, chronic hypoxia has also been shown 
to contribute to regression [34, 35]. Moreover, several 
studies have demonstrated that acute hypoxia increases 
cell survival and autophagy, selecting for cancer cells 
with stem cell characteristics, enhancing stem-like cell 
marker expression and endow resistance to radiotherapy 
[36–39]. Chenet al, showed that acute hypoxia, but not 
chronic hypoxia, induces genetic, molecular, biochemi-
cal, and cellular alterations promoting tumor cells with 
greater survival, heterogeneity, plasticity, tumorigenic 
capacity and resistance to anoikis, and thus enhanced 
ability for metastasis. In this study, HIF-1α expression 
was lost during chronic hypoxia, when HIF-2α mediated 
hypoxic responses may still be present [40].
Hypoxia and angiogenesis
Tumor cells adapt to reduced oxygen levels by promot-
ing the development of new blood vessels, a process 
termed angiogenesis [41]. Pro-angiogenic factors and 
their receptors including vascular endothelial growth 
factor (VEGF),VEGF receptor-1,-2 (VEGFR-1,-2), basic 
fibroblast growth factor (bFGF), platelet derived growth 
factor B (PDGF), insulin-like growth factor II (IGF2), 
adrenomedullin, and epidermal growth factor (EGF) are 
targets of the HIF transcription factors, and provide a 
molecular mechanism by which hypoxia regulates angio-
genesis [42]. Several of these angiogenesis-related gene 
products, including iNOS, endothelin, adrenomedullin, 
and heme oxygenase 1, are also implicated in the modu-
lation of local blood flow by regulating the vascular tone 
[43].
New vessels develop under hypoxic conditions but 
display substantial abnormalities, including; (i) an unu-
sually elongated and tortuous shape, sometimes with 
blind-ends causing geometric resistance, and which leads 
to a disruption in blood flow and intermittent stasis, (ii) 
increased dilations and permeability due to insufficient 
smooth muscle cell layer, discontinuous endothelium or 
absent endothelial cell lining and basement membranes, 
(iii) a deficiency in pharmacological/physiological recep-
tors and contractile wall components [20, 44].
Therefore, the tissue responses to ameliorate an 
impaired oxygen supply still fail [45]. Furthermore, due to 
a more access of metastatic cells to blood vessels, angi-
ogenesis associated with a more invasive tumor pheno-
type [46, 47]. Angiogenesis is also an important step in 
carcinogenesis and transition from hyperplasia towards 
neoplasia [48].
Signaling pathway for angiogenesis
Angiogenesis ismediated by the release of VEGF, the 
major hypoxia-inducible angiogenic stimulator, and 
this is driven by HIF.HIF-1 influences tumor blood flow 
through more complex mechanisms; HIF-1 targets differ-
ent genes playing the role in vessel tone.
Information regarding the role of HIF2-α in hypoxia-
related angiogenesis in tumor microenvironment is more 
controversial than for HIF-1α. Deletion of the HIF-1α 
gene in endothelial cells (EC), has been reported to 
reduce neovascularization and tumor growth, by disrupt-
ing the VEGF-mediated autocrine loop in EC, which is 
an essential component of solid tumor angiogenesis [49]. 
But, Skuli et al. [50], have demonstrated that HIF-2α gene 
deletion increased angiogenesis, albeit with more dis-
organized vessels resulting in poor perfusion and more 
hypoxic tumors in limb ischemia and autochthonous skin 
tumor models. They suggested that HIF-1α and HIF-2α 
act independently in response to local hypoxic stress, as 
HIF-1α promotes growth, proliferation, and morpho-
genesis in endothelial cells, while, HIF-2α is required for 
effective vessel remodeling and induction of a mature, 
functional vascular network. Conversely, this group of 
investigators had been previously reported that HIF-2α 
deletion resulted in reduced tumor angiogenesis, as well 
as increased vessel permeability and loss of integrity with 
a variable morphology in different adult organs [51]. 
These inconsistencies may be partly related to different 
expression patterns of HIF-2α in different tissues and its 
related cell type-specific signaling pathways [52]. HIF-1α 
and HIF-2α partially compensate for each other, how-
ever, they independently promote the modulations in the 
context of pathophysiological hypoxia to produce a func-
tional vasculature [53, 54].
The effect of hypoxia on cancer stem cells
There is mounting evidence that hypoxia affects the 
maintenance and functions of CSCs. CSCs constitute 
an undifferentiated stem-like cell subpopulation within 
the tumor heterogeneous cell types, which contributes 
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to cancer initiation, progression, metastasis, therapeu-
tic resistance and cancer relapse.
In solid tumors and hematological cancers, CSCs 
possess common properties to their normal stem cell 
counterparts, including self-renewal and the capac-
ity to give rise to various cell types [55]. Furthermore, 
CSCs have the capacity for sphere formation. Although 
there are some potential markers suggested for CSCs 
in hematological cancers, definitive universal mark-
ers for CSCs in solid tumors remain unknown [56, 57]. 
CSCs appear to ‘educate’ neighboring cells to provide 
nutrients, cooperate in their evasion from the immune 
system, and create a microenvironment favoring tumor 
growth. CSCs can be differentiated into various cells 
that may be found in the tumor, which is associated 
with their high plasticity [58], establishment of a qui-
escent state with basal activity [59], enhanced survival 
ability in a stressful tumor environment with reduced 
oxygen and nutrient levels, and increased resistance to 
chemo-, radio- and immuno-therapy, and therefore uti-
lized by tumors to escape from treatment and leads to 
recurrence [60]. Normal stem cells, such as hematopoi-
etic stem cells, are retained in an hypoxic zone distant 
from the vasculature, which aids the maintenance of 
their stem cell properties [61]. While increased oxygen 
levels lead to the loss of these properties (stem and pro-
genitor features referred to as stemness) [62]. Likewise, 
CSCs tend to localize to hypoxic regions within tumors, 
which probably favor the preservation the stem-ness, as 
well as to generate highly invasive and tumorigenic cells 
[63]. In conformity with this, Jogi et al., have reported 
that hypoxic cells in neuroblastoma (NB) adopt an 
immature phenotype [64]. It seems that cells in hypoxic 
areas, within the TME, are less mature and more inva-
sive than oxygenated cells, and display a stem cell-like 
phenotype. [65].
HIF signaling plays a significant role in the modula-
tion of various signaling pathways, which are exploited by 
CSCs to regulate stemness during hypoxic and therapeu-
tic stress [66–68]. These pathways include Notch, Hedge-
hog, Hippo, Wnt (wingless)/β-catenin, Janus-activated 
kinase/signal transducer, activator of transcription (JAK/
STAT), phosphatidylinositol 3-kinase/phosphatase, ten-
sin homolog (PI3K/PTEN), and nuclear factor-kB (NF-
kB) pathways. [69–71].
There is a growing body of evidence that implicates the 
reliance of CSCs on HIFs for the maintenance of their 
phenotype and function [68]. HIFs induce numerous 
gene products, including pluripotency related transcrip-
tion factors, epithelial to mesenchymal transition (EMT) 
programmer, glycolysis-associated molecules, drug 
resistance-associated molecules, miRNAs and VEGF [68, 
72].
Hypoxia‑mediated upregulation of pluripotency gene
HIF signaling enhances the maintenance of a CSC phe-
notype through the regulation of octamer-binding tran-
scription factor 4 (Oct4), sex determining region Y box 2 
(SOX2), kruppel-like factor 4 (KLF4), myelocytomato-
sis oncogene product (Myc), Tir nan Og (NANOG) and 
polycomb complex protein BMI-1 (BMI1) [72, 68].
Though both HIFs participate in CSCs survival and 
stemness maintenance [73, 74], hypoxia mediated tran-
scription of stem-ness genes is differentially regulated 
by HIF-1α and HIF-2α. HIF-1α triggers Nanog, whilst 
HIF-2α activates Oct4 and c-Myc transcription [75–77]. 
Moreover, the HIFs contribute to the induction of CSC 
trait in different manner, with greater involvement of 
HIF-1α for survival functions and more specificity of 
HIF-2α for stem-ness properties (i.e. self-renewal) [78]. 
Bae et al. showed that the role of HIFs in CSCs function 
is dependent on the duration of exposure to hypoxia. 
HIF-1α enhances the expression of stem cell marker 
SOX2 and acute hypoxia-mediated cell invasion, while 
HIF-2α elevates the chronic hypoxia-mediated SOX2 and 
sphere formation in prostate cancer [79]. There is some 
evidence for the stronger induction of CSCs by HIF-1α 
in hypoxic areas during tumor development, and for 
HIF-2α as the main HIF factor under normoxic condi-
tions that follow after cancer therapy, leading to a reduc-
tion in tumor size [80]. Consistent with this, Johansson 
and colleagues show that the expression of HIF-2α is 
significantly enhanced under normoxic and hypoxic con-
ditions in glioma stem cells (GSCs). Also, the intracel-
lular domain of CD44, a stem cell marker, is released in 
hypoxia, and binds to HIF-2α, but not HIF-1α, and sub-
sequently upregulates hypoxia-induced stemness genes 
in GSCs [81].
Hypoxia‑mediated induction of EMT
There are experimental and clinical data suggesting that 
CSCs are strongly linked to EMT. EMT contributes to 
tumor aggressiveness, by promoting tumor cell inva-
sion and migration, induction of stem cell phenotype, 
and subsequent therapeutic resistance leading to tumor 
recurrence [82–85]. Hypoxia, via HIF signaling, has 
been recognized to induce EMT and CSC features. Dur-
ing this phenomenon, tumor cells detach and acquire a 
mesenchymal phenotype, display the stemness prop-
erties including loss of differentiation, tumorigenesis 
and increased resistance to therapy [85]. Hypoxia/HIF-
induced EMT and CSC phenotype mediated by similar 
signaling pathways consisting of NF-κB, PI3K/Akt, Wnt/
β-catenin, Hedgehog and Notch [86]. A recent study also 
demonstrated that common genes are involved in EMT 
and a stemness phenotype, which contribute to tumor 
plasticity in response to anti-cancer therapies [87].
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Hypoxia‑mediated miRNAs
Recent findings have been provided evidence that 
support the responsiveness of a variety of miRNAs to 
hypoxia that play pivotal role in many aspects of tumor 
development and malignancy, including angiogene-
sis, metabolic adaptation, EMT and CSCs sustenance. 
Hypoxia can down regulate the expression of miR-20, 
miR-22, miR-101 and let-7, as well as up regulate the 
expression of miR-21, miR-107, miR-181b, miR-210, 
and miR-373 in tumor cells. Hypoxia often up regu-
lates oncogenic miRNAs and down regulates anti-
tumorigenic miRNAs and thereby are associated with a 
poor clinical prognosis [86, 88]. However, it has been 
reported to be associated with an increase in anti-tum-
origenic miRNAs such as miR-107. Therefore, more 
investigation is required to demonstrate the role of 
these miRNAs in stemness regulation and tumor pro-
gression under hypoxic conditions. Hypoxia-mediated 
miRNAs in TME that possess the ability of stemness 
regulation is summarized in Table 1.
Hypoxia‑mediated angiogenic factors
HIFs up regulate the expression of angiogenic factors, 
particularly VEGF in CSCs and promote tumor angio-
genesis [151, 152]. In addition to stimulation of angio-
genesis, hypoxia-induced VEGF is known to drive EMT 
and maintain CSC stemness, and by these mechanisms 
contributes to tumor invasion and metastasis [153, 
154].
Hypoxia‑mediated metabolic adaptation
Hypoxia-induced metabolic reprogramming can also 
contribute to CSC maintenance and resistance [68]. In 
most cases, the principal metabolic pattern in normal 
stem cells is glycolysis whereas differentiated cells pri-
marily perform oxidative phosphorylation (OXPHOS). 
Meanwhile, CSCs do not resemble the metabolic pat-
tern of normal stem cells. Indeed, both glycolysis and 
OXPHOS are metabolic engines in CSCs, and predomi-
nant metabolic pattern depends on the type of tumor 
and TME stimuli [155]. The hallmark of hypoxia-
induced metabolic reprogramming is a shift in ATP 
production from OXPHOS to glycolysis. Under hypoxic 
conditions, HIF-1α (and HIF-2α) that is stabilized in 
CSCs, triggers the expression of genes involved in met-
abolic adaptation (e.g., GLUT1, LDH -A, PDK) [77]. 
Consequently, lactate increased and levels of ROS are 
reduced, in turn leading to CSC protection and poten-
tially therapy failure [156]. Evidences show that high 
level of lactate and acidic stress in the microenviron-
ment induce CSC phenotype [157], tumor invasiveness, 
and impair the immune response [158, 159]. Acidic 
stress is considered to be a mechanism for HIF-2α 
induction, in which HIF-1α can upregulate HIF-2α acti-
vation via metabolic pathways [160].
There is some evidence for a link between high levels of 
aldehyde dehydrogenase (ALDH), the enzyme responsi-
ble for oxidizing intracellular aldehydes, and response of 
CSCs to hypoxia. Shiraishi and colleagues, showed that 
under hypoxic conditions, the expression of ALDH1A1 
is associated with the overexpression of HIF-1α, but not 
HIF-2α, and stemness in breast cancer stem cells (BCSCs) 
[161]. Kim and colleagues, however, showed that ALDH 
was highly associated with the HIF-2α expression of 
breast cancer cell lines in vitro and self-renewal ability of 
BCSCs in mouse model of breast cancer [162]. Regard-
less of HIFs, overexpression of the membrane-bound 
ectoenzymes carbonic anhydrases (CAIX and CAXII) 
and monocarboxylate transporter-4 (MCT-4) in response 
to hypoxia, promotes a CSC phenotype and function, by 
modifying acidic pH of hypoxic cancer cells with a high 
rate of glycolytic metabolism [163, 164].
Hypoxia‑mediated quiescence
By modulation of the process of metabolic adaptation, 
apoptotic pathways, cell cycle and self-renewal, hypoxia, 
maintains the CSCs in the quiescent state. Quiescence 
defined as a protective response to adverse condition, 
enabling cells to conserve the proliferative potency and 
eliminate DNA damage [165]. Non-dividing quiescent 
CSCs that can survive after conventional therapy target-
ing rapidly dividing cells, are responsible for the failure 
of cancer therapy and tumor relapse [166]. Prati and col-
leagues demonstrated that under chronic hypoxic stress, 
breast cancer cells enter into quiescent state, character-
ized by cell-cycle arrest in G0/G1 and lower levels of 
metabolism. These dormant cells have a CSC phenotype 
and sphere-forming capacity [167].
One of the major regulators that contributes to the 
induction of cell-cycle arrest, and quiescence, during 
hypoxia, is HIF-1α, that acts independently of p53 and 
causes the up-regulation of cyclin-dependent kinase 
inhibitors p21 and p27, hypophosphorylation of RB 
and suppression of cell cycle gene CDC25A [168, 169]. 
However, it has been reported that the de-depression of 
cyclin-dependent kinase inhibitors, such as p21, is not 
essential for HIF-1α-induced quiescence [170]. Also, 
HIF-1α+ quiescent stem-like cells are associated with 
increased sphere-forming capacity and higher tumori-
genicity in glioblastoma patients [171]. Although, HIF-1α 
can promote cell-cycle arrest by inhibiting c-Myc activity 
[172], HIF-2α has been shown to stimulate the progres-
sion of the cell-cycle and neoplastic growth of cancer cell, 
via functional enhancement of c-Myc [76]. The induc-
tion of quiescence by HIF-1α may appear to contradict 
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some evidence from its role in cancer growth. However, 
HIF-1α may temporally maintain cancer cells in a quies-
cent state and conserve their survival as long as oxygen 
supply is available, where they become more invasive.
Hypoxia‑mediated resistance
Hypoxic CSCs also have a high expression of a number of 
Adenosine triphosphate–binding cassette (ABC) trans-
porters, including multidrug resistance gene 1 (MDR1 
or ABCB1) and its product permeability glycoprotein 
(P-glycoprotein), multidrug resistance-associated pro-
tein (MRP1), breast cancer resistance protein (BCRP or 
ABCG2 or MXR) and ABCB5 [78]. These membrane 
transporters as a feature of stem-like cells, and contrib-
ute to transporting cytotoxic materials out of cell. CSCs 
exploit the BCRP to offset the detrimental effect of heme 
or porphyrin accumulation, under hypoxic condition 
[173]. The ABC transporters, further, provide a high 
capacity efflux system, leading to chemotherapy failure 
and highly drug-resistant tumor formation [174]. HIFs 
play the role in the activation of drug transporter in CSCs 
upon hypoxic condition. The HIF-mediated increased 
expression of these transporter reduce the effect of 
chemotherapeutic agents, including paclitaxel, gemcit-
abine and Imantinib [175, 176]. Both HIF-1α and HIF-2α 
participate in the up-regulation of ABC transporters and 
chemo-resistance, but in different capacities. With a cen-
tral role of HIF-1α for MDR1 activation and partial par-
ticipation in BCRP and MRP1 activity, as well as more 
responsibility of HIF-2α for BCRP activation and less rel-
evance to MDR1 control [177].
The role of hypoxia in cancer progression, 
metastasis, immunosuppression, and treatment 
resistance
Hypoxia can substantially affect the malignant progres-
sion and therapeutic response of solid tumors by change 
the transcriptome and regulating the production of pro-
teins in tumor cells that modulate immune privilege and 
limit anticancer immunity [178]. Thus, hypoxic condition 
often linked to a poor prognosis of many cancers. Con-
versely, some evidences implicate the augmentation of 
anti-tumor response by hypoxia associated factors.
Hypoxia‑induced cancer progression and metastasis
Hypoxia may facilitate the dissemination of cells from 
the tumor to the other region of the body, by reducing 
the strength of interactions between cells and their sup-
porting extracellular matrix (Fig. 1a). Czekayet al. [179], 
have shown that plasminogen activator inhibitor-1 (PAI-
1) has a de-adhesive activity, as well as other de-adhesion 
molecules that include: thrombospondins (TSPs) 1 and 
2, tenascin-C, and SPARC(secreted protein, acidic and 
rich in cysteine) [180]. These proteins can reverse the 
cell adhesion process and disrupt the integrin-mediated 
cell attachment. Consistent with this, high levels of PAI-1 
have been reported to be associated with a poor progno-
sis in metastatic human cancers [181, 182].
Furthermore, vascularization, as an important conse-
quences of HIF signaling, has emerged as a fundamen-
tal feature of neoplastic growth, tumor progression and 
distant metastasis. Excessive blood vessel formation 
gives the weakly attached tumor cells a greater chance to 
enter into the circulation and migrate (Fig. 1b) [46, 47]. 
Fig. 1 The diagram displays the responses to reduced oxygenation within the tumor microenvironment. Hypoxia promotes tumor invasion, 
metastasis and resistance through several ways. a Hypoxia induces detachment of tumor cells by weakening the connections between cells and 
their extracellular matrix supporting them, and promotes dissemination of tumor cells to the various organs of the body. Thereby hypoxia triggers 
the metastatic spread of tumor. b Hypoxia stimulates angiogenesis, and provides more opportunity for detached tumor cell to inter into the 
circulation and migrate via the newly formed vessels. Thereby hypoxia enhances invasive and metastatic spread of solid tumors to another region. 
c Hypoxia induces EMT, in which tumor cells detach, lose the epithelial feature, acquire a mesenchymal phenotype and display the stemness 
properties including loss of differentiation, tumorigenesis and aggressiveness. EMT extensively contributes to promoting of tumor cell invasion 
and migration. d Hypoxia up-regulates CAFs that produce the excessive altered ECM, which supports tumor growth and metastasis. e Tumor 
hypoxia promotes secretion of cytokines and chemokines that recruit pro-tumor immune cell and suppress anti-tumor response of various types 
of immune cells. f In response to hypoxia, tumor cells exploit a number of mechanisms including, extrusion of cytotoxic drug by ABC-transporters, 
exhibiting quiescent state, acquiring metabolic adaptations and displaying stemness features, which can contribute in chemo-, radio- therapy 
failure. g Hypoxia acts as a niche condition, to accumulate the CSCs enhancing tumorigenesis and resistance. EMT epithelial to mesenchymal 
transition, CAF cancer-associated fibroblast, ECM extracellular matrix, MDSCs myeloid-derived suppressor cells, TAM tumor-associated macrophage, 
TAN tumor-associated neutrophil, Treg regulatory T lymphocyte, NK cell natural killer cell, CSC cancer stem cell
(See figure on next page.)
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Thereby, hypoxia triggers the escape of tumor cells from 
the hostile environment and enhances the invasiveness 
and metastatic spread [183, 184].
EMT is another process promoted by hypoxia. Tumor 
cells, which undergo EMT, are reprogramed to have 
greater mesenchymal features, reduced intercellular 
attachments and cell-to-cell contacts, increased motil-
ity, and conversion to a stem-like phenotype. Thereby, 
hypoxia-induced EMT increases the aggressiveness 
and metastatic potential of these cells (Fig.  1c) [84, 85]. 
Expression of lysyl oxidase (LOX) and lysyl oxidase-
like 2 (LOXL2) and HIF-1 accumulation, downregu-
lates E-cadherin and leads to EMT, which contributes 
to renal, breast and cervical cancer progression and 
metastasis [185–188]. HIF-1, also contributes to EMT 
induction in VHL-null renal cell carcinoma by indirect 
Tumor dissemination CSC development Tumor resistance g fa
b e
c d
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repression of E-cadherin, mediated by the expression of 
TCF3, ZFHX1A, and ZFHX1B [189]. Moreover, HIF1-α 
increases the transcriptional repressor SNA, and down-
regulates E-cadherin in ovarian carcinoma cells [190]. 
Kang and colleagues, also showed that the hypoxia-
induced EMT is associated with increased CXCR4 
expression via of aberrant demethylation of its promoter 
in lung cancer cell, in which, CXCR4 siRNA inhibits the 
hypoxia-induced EMT and acquisition of stemness [191].
Moreover, hypoxia has been shown to influence fibro-
blast reprogramming and upregulate cancer-associated 
fibroblasts (CAFs) in HIF-1α dependent manner with 
a metabolic shift towards glycolysis, and that leads to 
an increase in lactate production. This catabolite is pro-
duced by highly glycolytic CAFs and can be used by 
cancer cells and enhances cancer proliferation, which 
describes a negative outcome of HIF-1 accumulation in 
fibroblasts [192, 193]. CAFs share several characteristics 
with normal fibroblasts that are activated, but they pos-
sess oncogenic functions substantially due to production 
of altered ECM, which supports tumor growth and dis-
semination (Fig.  1d) [194]. The ECM produced by can-
cer cells and CAFs in hypoxia, differs from the normoxic 
ECM and continuously undergo remodeling, which facil-
itates angiogenesis [195], tumor cell migration and meta-
static spread [196, 197].
Hypoxia‑induced cancer immunosuppression
By influencing various types of immune cells, hypoxia 
has been associated with immunosuppression and subse-
quent tumor progression (Fig. 1e) [198].
The characteristics of the hypoxic tumor microenvi-
ronment, are frequently reported to correlate with the 
accumulation and augmentation of MDSCs. Hypoxic 
tumor cells can produce CCL26 to attract MDSCs and 
their homing to the primary tumor [199]. The major 
feature of these heterogeneous undifferentiated cells, is 
the exhaustion and suppression of immune cells, which 
in tumor context leads to evasion from immune surveil-
lance and bypass the blockade of immune checkpoints. 
One of the underlying mechanism reported in 2017, in 
which hypoxia/HIF-1α induces ectonucleoside triphos-
phate diphosphohydrolase 2 (ENTPD2/CD39L1) in can-
cer cells result in overexpression of extracellular 5′-AMP, 
which maintains MDSC in undifferentiated and immu-
nosuppressive state in the tumor stroma [200]. However, 
Corzo et  al. [201] reported that HIF-1α mediates, the 
rapidly differentiation of MDSCs into macrophages with 
immune-suppressive features upon their arrival at tumor 
sites. They also described differences between MDSCs in 
tumor site, contrasted with MDSCs located in periph-
eral lymphoid organs, that acquire the ability to suppress 
antigen-nonspecific T cell, as a result of hypoxia induced 
upregulation of inducible nitric oxide synthase (iNOS) 
and arginase I, and associated downregulation of both 
nicotinamide adenine dinucleotide phosphate–oxidase 
2(NOX2) and reactive oxygen species (ROS). In addi-
tion, hypoxia can enhance MDSCs activities through a 
HIF1α-dependent mechanism and subsequently elevates 
miR-210 expression. miR-210 regulates the function of 
MDSCs by increasing arginase activity and nitric oxide 
production [202]. Although it is widely accepted that 
MDSCs have immunosuppressive activity, some studies 
have found immunostimulatory properties of M1 type 
MDSCs, compared to the suppressive M2 phenotype 
[203]. SIRT1 induction and mTOR/ HIF-1α-dependent 
glycolytic reprogramming, has been found as an underly-
ing mechanism in lineage differentiation of MDSCs into 
the tumor-suppressing M1 phenotype [204].
Under hypoxic condition, tumor cells promote the 
secretion of chemoattractive substances, including 
hypoxia-induced Semaphorin 3A (Sema3A), Endothelial-
monocyte-activating polypeptide II (EMAPII), ET-1 and 
ET-2, which promote recruitment of macrophages [205–
207]. As hypoxia triggers the switch to glycolysis and 
increases lactate and  H+ production, it can also promote 
M2 polarization of tumor-associated macrophages [208]. 
Activated M2 macrophages, in contrast to their classi-
cally activate M1 counterparts, have more capacity to 
induce angiogenesis and tumor progression and metas-
tasis. Besides accumulation of macrophages, hypoxia 
strongly augments macrophage-mediated T-cell suppres-
sion in a HIF-1α dependent manner. Nevertheless, both 
of HIF1-α and HIF2-α have been shown to be pivotal for 
macrophage infiltration and immune suppression [209, 
210].
Neutrophils infiltrating into the tumor microenvi-
ronment, are known as tumor-associated neutrophils 
(TANs), and are a heterogeneous population includ-
ing anti-(N1) and pro-tumor (N2) phenotypes [211]. 
Tumor hypoxia is one of the factors can influence neu-
trophil plasticity [212]. However, the mechanism by 
which hypoxia/HIFs affects the N1 and N2-polarization 
of TANs remains to be clarified. Reciprocally, neutro-
phils enhance micro-environmental hypoxia by depleting 
localized oxygen, resulting in upregulation of hypoxia-
inducible genes [213]. Hypoxia, through HIF-dependent 
production of cytokines (IL-8) [214], and chemokines 
(CXCL1, CXCL2, and CXCL5) [215] can recruit TANs. 
In addition, hypoxia upregulates the expression of the cell 
surface adhesion molecule β2 integrin in neutrophils and 
enhances their function, in a HIF-1α dependent manner 
[216]. HIF-2α is a critical mediator of neutrophil recruit-
ment to colon tumors and subsequent increase of colon 
carcinogenesis, by upregulating the potent neutrophil 
chemokine CXCL1 [217]. Local hypoxia have been shown 
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to promote neutrophil extracellular traps (NETs) [218], 
which consist of expelled DNA and various proteins such 
as neutrophil elastase (NE). NETs promote angiogenesis, 
cancer progression and metastasis [219–221]. Moreover, 
TGF-β, as a known target of HIF-1, reported to induces 
a pro-tumor N2 phenotype of TANs [222]. It is appear 
that hypoxia causes a shift of N1 toward N2 TANs, which 
supports tumor progression and metastasis [212].
The metabolic competition between tumor cell and 
infiltrating lymphocytes, leads to a limitation of glyco-
lysis in tumor-infiltrating T cells [223–225], hypoxia can 
suppress the anti-tumor activities of T cells through the 
other mechanisms mediated by HIF. Regulatory T-cell 
(Treg) repress the anti-tumor responses and addressed as 
an important limitation of cancer immunotherapy [226, 
227]. Tumor cells under hypoxic conditions, upregulate 
the expression of chemokines and cytokines, such as CC-
chemokine ligand 28 (CCL28) and VEGF, which attract 
Tregs (CD4 + CD25 + FoxP3 + nTreg) to suppress tumor-
reactive T cells and promote angiogenesis [228–231]. 
Hypoxia induces FoxP3 and promotes the differentiation 
of Tregs (iTregs) from naive T cells through T-cell intrin-
sic HIF-1α pathway [232]. Indeed, hypoxia is considered 
to be an indicator of the inflamed microenvironment, 
and an increase the proportion of Tregs is an anti-inflam-
matory mechanisms to restrict the detrimental effects of 
inflammatory hypoxia [233]. In contrast, there is emerg-
ing evidence that shows that HIF-1α possesses a deleteri-
ous effect in suppressive activity and stability of Tregs by 
degradation of FoxP3, and implicates a role for HIF-1α in 
development and function of Tregs [234, 235].
Another mechanism by which hypoxia represses the 
anti-tumor response involves the modulation of immune 
checkpoints. HIF1-α, and occasionally HIF2-α, upregu-
lates the immune inhibitory molecule programmed cell 
death ligand-1 (PD-L1; also termed B7-H1) in hypoxic-
tumor cells, macrophages and MDSCs [236–239]. Fur-
thermore, HIF-1α enhances the expression of inhibitory 
receptors including programmed cell death 1 (PDCD1; 
also termed PD-1), lymphocyte activating gene 3 (LAG3, 
also termed CD223) and CTLA-4 in  CD8+ T cells [240, 
241]. Hence, hypoxia promotes T cell exhaustion and 
tumor resistance to CTL-mediated lysis.
In contrast to what is described above, a potential 
adverse effect of hypoxia on tumor-reactive T cells, has 
been shown; in respect of the stimulatory role mediated 
by HIF1-α and HIF-2α in CTL proliferation and function 
[242]. Mohapatra et al. found that in glioblastoma (GBM) 
[243] there was a downregulation of immunosuppressive 
enzyme tryptophan-2,3-dioxygenase (TDO2) involved 
in tryptophan (Trp) catabolism, in a HIF1α-dependent 
manner, with increased T cell proliferation. While, T cell 
proliferation is inhibited by TDO2-expressing GBM cells 
under normoxia. Its assumed that tumor cells downregu-
late TDO2 to conserve Trp through HIF1-α in a nutrient-
deficient hypoxic microenvironment. Consistent with 
this, Tyrakis et  al. [244] were able to show an enhance-
ment of proliferation, survival and anti-tumor capacity 
of  CD8+ T cells by hypoxic induction of 2-hydroxyglu-
tarate through the HIF-1α dependent fashion. Moreover, 
hypoxic CTLs exhibited higher intrinsic cytotoxic capac-
ity and improved function in tumor regression compared 
to normoxic CTLs [245]. However, hypoxia was shown 
to negatively regulate the interplay between NK cells and 
tumor cells. In hypoxia HIF-1α upregulates the metal-
loproteinase ADAM10 that leads to shedding of the NK 
cell-activating ligand, MICA, from the surface of tumor 
cells, results in resistance to cytotoxic killing by NK cell. 
Mechanism of this NKG2DL shedding involves impaired 
nitric oxide (NO) signaling [246, 247]. Thereby hypoxia 
contributes to escape from innate immunity. In contrast, 
the supporting role of hypoxia in NK cell priming and 
activation, in synergism with IL-15, has been reported 
[248, 249].
Hypoxia‑induced cancer resistance
Resistance to conventional treatment is a major obstacle 
in clinical oncology that lead to cancer relapse. Oxygen 
deprivation may cause in resistance to ionizing radia-
tion, multiple forms of chemotherapy and photodynamic 
therapy. Several mechanisms of hypoxia-induced resist-
ance related to cellular adaptations to poor oxygenation 
and nutrition (Fig. 1f ). Hypoxia promotes cell cycle arrest 
and a quiescence cellular state that reduces the suscep-
tibility to external stress during radiation or chemo-
therapy, especially therapies targeted at rapidly dividing 
cells [63]. Hypoxia increases the synthesis of certain pro-
teins in subclones, undergoing selection pressure. Con-
sequently, during clonal selection and genome changes, 
tumorigenic subpopulations are formed which related to 
a lack of differentiation, defective senescence and apop-
tosis, augmented spreading and metastasis can lead to 
further resistance to therapy [29, 63, 250]. Moreover, 
hypoxia modulates mitochondrial activity [cell apoptosis 
and necroptosis, as well as generation of reactive oxygen 
species (ROS)] and induces mitophagy. Thereby, hypoxia 
reduces the susceptibility of tumor cell to drug- and radi-
ation-induced apoptosis and ROS formation [251, 252]. 
Modulation of autophagy and p53 known as another 
mechanism involved in the hypoxia-induced resistance 
to chemotherapy, however their molecular pathways 
remained largely elusive [253, 254].
In addition, loss of oxygen required for the cytotoxic 
function of the certain chemotherapeutics, orienta-
tion of chaotic and malfunctioning blood vessels, and 
augmentation of metastasis [255], reduction of drug 
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delivery and cellular uptake due to tissue acidosis, 
overexpression of the multidrug resistance (MDR1) 
gene [256] and its product P- glycoprotein (drug efflux 
pump) [257, 258], enhanced production of nucleophilic 
substances such as glutathione, which compete with the 
target DNA for alkylation, and upregulated enzymatic 
repair of DNA, are other possible mechanisms by which 
hypoxia reduces the responsiveness to chemotherapeu-
tic agents [259].
Vasculogenic mimicry (VM) is a major factor in metas-
tasizing breast cancer and resistance to anti-angiogenic 
drugs. Hypoxia, EMT and CSC are considered as impor-
tant factors in the formation of VM. Melatonin is also 
a hormone derived from amino acids, with many anti-
tumor effects. There are numerous antitumor effects of 
melatonin, but its effect on breast cancer VM formation 
has not yet been investigated. Therefore, we investigated 
the impact of melatonin in breast CSCs on VM forma-
tion via the EMT cycle under hypoxia conditions. We 
evaluated the impact of melatonin on the EMT markers 
expression. As a CSC marker in the MDA-MB-231 cell 
line, CD44 + CD24-phenotype was 80.8 percent whereas 
in the MCF-7 cell line it was 11.1 percent. The expres-
sion of HIF-1α in the VM-positive breast cancer cell line 
MDA-MB-231 was up-regulated and thus influenced the 
expression of the EMT markers E-cadherin, vimentin, 
snail and MMP9. Melatonin in breast CSCs had major 
effects on EMT and VM formations. Melatonin may 
hinder VM formation by influencing the key molecules 
taking part in VM structure and the EMT formation. In 
addition, our results demonstrate obviously that mela-
tonin is a hormone with important anti-cancer activity. 
It may probably improve breast cancer management via 
overcome anti-angiogenic drug resistance [260].
Notwithstanding, these mechanisms that are princi-
pally mediated by the HIF-1, the roles of HIF-2 in resist-
ant to anticancer therapy is recently reported, including 
its roles in affecting HIF-induced autophagy and hamper-
ing p53-mediated apoptosis [261, 262].
Recent evidence also suggests that resistance is largely 
linked to the function of CSCs [166]. As previously 
described, hypoxic areas within the TME provide a niche 
for development and accumulation of CSCs, which are 
poorly differentiated and more invasive, enhancing tum-
origenesis and resistance to chemo-, radio- and immuno-
therapy (Fig. 1g).
Strategies to re-engineer the tumor 
microenvironment for treatment
Hypoxia is a major feature of solid tumors and an impor-
tant impediment to conventional cancer therapy. Iden-
tification of the predominant cellular and molecular 
mechanisms in hypoxic TME presents the first step to 
design of effective anti-cancer strategies in the context of 
solid tumors.
Targeting HIFs as a therapeutic strategy
Given that HIF proteins are the master regulators of 
oxygen homeostasis in hypoxia, targeting HIFs is an 
attractive strategy in the treatment of tumors. Sev-
eral approaches for targeting hypoxia and HIF may be 
achieved by exploiting; (1) hypoxia-activated prod-
rugs (HAPs) or drug; (2) specific targeting of HIFs; (3) 
targeting of downstream HIF signaling pathways and 
important pathways in hypoxic cells (such as mTOR and 
UPR).
HAPs, which also known as bioreductive alkylating 
agents, can directly or indirectly regulate HIFs. HAPs 
are inactive compounds that can be activated to cyto-
toxic drugs in hypoxic cells or tissues, spontaneously 
or via one/two electron oxidoreductases [263]. Several 
HAPs, including PR-104, Evofosfamide (TH-302), and 
apaziquone (EO9), have undergone preclinical study 
and clinical development. However the result of clini-
cal trials showed some disappointments and thus far 
there is no FDA approved HAP [264]. Fortunately, 
promising progress has been reported in phase II clini-
cal trial on TH-302 in combination with gemcitabine 
for pancreatic cancer [265], and with adriamycin or 
doxorubicin for soft tissue sarcoma [266], and phase 
III studies are underway. Furthermore, TH-302 sensi-
tizes prostate cancer to immunotherapy with check-
point blockades CTLA-4 and PD-1. Combination 
therapy with this hypoxia-prodrug and checkpoint 
blockade drive a more influx of T cells into hypoxic 
zones and reduce MDSC and granulocytic subsets in 
tumor environment [267].
The other approaches for overcoming hypoxia, involve 
direct or indirect targeting of HIF and targeting of down-
stream HIF signaling pathways. The agent exploited to 
inhibit the HIF response to hypoxia include inhibitor of 
HIF-1α mRNA expression (such as antisense oligonu-
cleotide EZN-2968), HIF-1α protein translation (includ-
ing inhibitors of topoisomerase I/II, receptor tyrosine 
kinase, cyclin-dependent kinase, oncogenic pathways, 
thioredoxin reductase, activators of p53 and microtubule 
disrupting agents), HIF-1α protein degradation (includ-
ing Hsp90 inhibitors such as 17-AAG and 17-DMAG), 
HIF-1α DNA binding (such as doxorubicin and dauno-
rubicin) and HIF-1α transcriptional activity (Bortezomib 
(PS-341) and chetomin) [268]. These inhibitors have 
been described in detail in several comprehensive reviews 
[18, 268]. Here we will summarize the strategies target-
ing the main pathways involved in hypoxia in tumor 
environment.
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Targeting angiogenesis as a therapeutic strategy
One good example of targeting gene products at down-
stream HIF signaling, is anti-VEGF therapeutic strategy. 
Anti-angiogenic approaches including monoclonal anti-
bodies (mAb) targeting VEGF or small-molecule inhibi-
tors targeting VEGF receptors can obviate the deleterious 
effects of angiogenesis in TME favoring tumor growth 
[269].
Bevacizumab (avastin) is a humanized anti-VEGF 
IgG1 mAb that has been approved for numerous recur-
rent and metastatic cancer. Ramucirumab is the anti-
VEGFR-2 IgG1 mAb and approved for the treatment of 
advanced and metastatic several types of cancer, includ-
ing stomach, colorectal and non-small cell lung carci-
noma (NSCLC) [269]. Another anti-angiogenic approach 
has been achieved through targeting Angiopoietin-1 or 2 
(Ang-1,2), using Trebananib. Angiopoietin displays broad 
expression in the remodeling vasculature of tumors and 
binds to its receptor, Tie-2. Trebananib is a “peptibody” 
madeas an antibody and peptide-Fc fusion protein that 
impairs the interaction between Ang-1,2and Tie-2, lead-
ing to the suppression of angiogenesis and tumor growth 
[270, 271].
Over the last few years, several small-molecule 
kinase inhibitors have been developed for treat-
ment of different cancers. For instance, sorafenib, 
regorafenib, lenvatinib, nintedanib, sunitinib, cabo-
zantinib and pazopanib that can inhibit several pro-
tein kinases including VEGF receptor (VEGFR), 
approved by the FDA for treatment of different can-
cers and as adjuvant for cancer chemotherapy. In 
addition, 1,2-disubstituted benzimidazoles, the newly 
synthesized compounds exhibits promising cytotoxic 
and VEGFR-2 inhibitory [272].
Despite the reported clinical benefits, anti-angiogenic 
therapies have been not shown to be always effective. 
Hypoxia induced in response to reduced perfusion dur-
ing anti-VEGF treatment promotes a greater depend-
ence on hypoxia adaptations, in particular, mediated by 
HIF1 and HIF2, the unfolded protein response (UPR) and 
ATF4 [269, 273]. For example, anti-angiogenic therapy 
promotes metabolic changes through HIF-1 expression, 
in turn increases lactic acid and carbonic acids produc-
tion. Therapy against VEGF, also, can promote the inher-
ent selection of tumor cells, which adapt to more hypoxic 
conditions. Furthermore, exaggerated hypoxia resulted 
following anti-VEGF treatment which favored a sus-
tained CSC phenotype, and which in turn may contrib-
ute to tumor maintenance and resistance to therapies 
[274]. Hence, an effective anti-angiogenic therapy may 
be achieved in combination with inhibitors of tumor 
hypoxic adaptation.
Targeting hypoxia‑induced metabolic changes 
as a therapeutic strategy
The accumulation of lactate in tumors results in reduced 
intracellular pH (pHi). Moreover, tumor cells in response 
to hypoxia, upregulate carbonic anhydrases and the pro-
duction of  CO2, which contributes to cellular acidifica-
tion [275]. To counteract acidification, hypoxic tumor cells 
upregulate a number of membrane transporters, exchang-
ers and pumps and release the lactic acid into extracellular 
space. Further, they upregulate extracellular carbonic anhy-
drases (CAs) catalyzing the hydration of CO2 to bicarbo-
nate, which pumped in and in turn increases the pHi and 
acidifies the extracellular pH (pHe) [276]. The other impor-
tant transporters, involved in the export of proton from 
cells, include the sodium hydrogen exchanger 1 (NHE1) 
and monocarboxylic acid transporters (MCTs) [277, 278]. 
Also, ion channels such as transporters, exchanger, pumps 
and voltage gated sodium channels, endow the tumor with 
the proliferative, invasive and metastatic ability [279]. These 
channels modulate tumor cell survival, proliferation, resist-
ance to apoptosis, cell adhesion, motility and extracellular 
matrix invasion [280, 281]. Given that the hypoxic tumor 
is dependent on glycolysis and pHi-regulating systems, 
ion channels have been recently proposed as a potential 
target for selective therapeutics. The strategy of ion chan-
nel blockades accompanies maintaining the low intracel-
lular pH in malignant cells, which induce acid-mediated 
metabolic collapse following by apoptosis or necrosis [282, 
283]. For instance, targeting of NHE1 recently reported 
to be effective in the treatment of glioblastomas, as highly 
glycolytic and strongly pH-dependent malignancies [284, 
285]. It has also been shown that proton pump inhibitors 
(PPI, V-ATPase blocker) increase the uptake and effect of 
cytotoxic drugs in chemo-resistant epithelial ovarian can-
cer [286]. Furthermore, MCTs (in particular, MCT-4, as 
hypoxia-inducible isoform and MCT-1) and CAs (in par-
ticular, CAIX and CAXII) have been offered the promising 
therapeutic targets for various cancer types, and recently, 
a large variety of inhibitors that target their different iso-
forms are being tested [277, 287]. Additionally, targeting of 
CAIX emerged as attractive strategy to eliminating CSCs in 
hypoxia [288, 289].
Targeting hypoxia‑induced metabolic changes to improve 
the efficacy of immunotherapy
A relatively low pH is a hallmark of solid tumor environ-
ments, with pH 6.0–6.5, compared to pH 7.5 present in 
normal environments [290]. High acidity associated with 
solid tumors acts as a barrier for immune-based thera-
pies such as checkpoint inhibitors or adoptive T-cell 
transfer [291]. This could, in part, be due to the adverse 
effect of acidity on different immune cells. Acidity leads 
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to a reduced lifespan of  CD8+ memory T cells [292], 
raise the activation threshold of T cells and modulate the 
activity of T cells by up-regulating the immune check-
points such as CTLA-4 [293]. High extracellular lactate 
can induce a tolerogenic phenotype of dendritic cells, 
characterized by reduced IL-12 and increased IL-10 
production in response to TLR stimulation, impaired 
migratory response to chemokines and defective metabo-
lism [294]. Chronic long-term exposure to acidic milieu 
of tumor, also, impairs NK cell activation, function and 
survival [293]. On the other hand, tumor acidity recruits 
MDSCs [294]. There is also evidence suggesting that low 
a pH decreases T cell infiltration and their homing into 
the TME.
Recently, Thomas and coworkers [295], examine the 
effect of pH buffering and neutralizing tumor acidity by 
oral bicarbonate administration, on anti-tumor responses 
to checkpoint immunotherapyand observed the increase 
of anti-tumor immunity in multiple cancer modelsOf 
note, acidity-reversing drugs appear to be artificially 
raised the pH of tumor vasculature, allowing to increase 
T cell homing at this site. In addition, pH gradient cre-
ated between intracellular and extracellular environ-
ments affects the drug absorption and metabolism, also 
suppresses cytoplasmic retention of cytotoxic anticancer 
agents [296], and thereby facilitates the acquired drug 
resistance.
Strategies to limit hypoxia‑induced radio‑ 
and chemo‑resistance
Recent studies show that a combination of supplemen-
tal oxygen therapy with cytotoxic drug or radiation 
therapy enhanced their effectiveness [297]. Anti-cancer 
drugs mostly kill cells in an oxygen-dependent man-
ner and require oxygen for maximal activity. Platinum 
based chemotherapeutic agents produced free radicals 
in tumor cells, which killed them by capturing electrons 
and delivered them to oxygen [298]. Moreover, many of 
these drugs have a large molecular weight, which makes 
their distribution difficult. This can be exaggerated in 
abnormal vascular network in hypoxic area within the 
solid tumors [299]. Hence, drug availability decreases to 
the levels less than the lethal dose [300]. In addition to 
this, upregulation of hypoxia-inducible genes involves 
in chemo-resistance. HIF-1 target hypoxia response ele-
ments (HREs) have been found in genes encoding mem-
bers of the ABC transporters such as MDR1 and BCRP, 
which their products actively extrude cytotoxic drug 
out of tumor cells [300, 301]. Hypoxia, also triggers the 
inhibition of DNA damage and decreased tumor cell 
senescence particularly in a HIF-1 dependent fashion. 
For instance, hypoxia inhibits etoposide-induced DNA 
damage [301]. Cell cycle regulation is an important 
determinant of tumor resistance [302]. Hypoxic tumor 
cells, especially being distant from blood supply, have 
downregulated cell cycle, which protects them against a 
variety of chemotherapeutic drugs targeted cellular DNA 
of dividing cells. Such cells also promote drug resist-
ance by altering metabolism and create acidic conditions 
as previously described [303]. Furthermore, hypoxia, 
considered as a main driver of autophagy, which have 
been accompanied with anti-cancer therapeutic resist-
ance. During autophagy, damaged cellular components 
degraded and tumor cell protected against apoptosis 
induced by chemotherapy and radiotherapy [304, 305].
Radiation therapy causes cell death by inducing DNA 
damage, which in the presence of oxygen leads to the 
generation of free radicals, failure to repair the damage 
and therefore becomes irreversible. While in hypoxic 
conditions, the ability of DNA repair increased, results 
in cell survival and remaining subpopulations responsi-
ble for poor outcome [306]. Evidence, also suggested that 
hypoxia might protect the CSCs to escape from lethal 
effects of radiotherapy [303]. In addition, radiation can 
induce transient oxygen fluctuation within the tumor, 
which leads to ROS generation and HIF-1 expression 
that in turn promote production of cytokines, VEGF and 
basic fibroblast growth factor (bFGF). They can eventu-
ally, prevent endothelial apoptosis, which provide an 
additional mechanism for radio-resistance [307]. Several 
strategies have been exploited to limit hypoxia-induced 
radio-resistance, such as increase oxygen availability 
through enhancement of blood flow, mimicking oxygen 
and targeting hypoxic tumor cells [301].
Modifying the exosome content in hypoxic tumor 
microenvironment
Hypoxia triggers exosomes secretion by tumor cells, 
however, increased exosomes secretion under hypoxic 
conditions is not a particular feature of tumor micro-
environment. Exosomes can change the phenotype of 
adjacent normal cells and other cells in the tumor micro-
environment as well as distant cells through systemic 
circulation promoting the formation of distant premeta-
static niches [308]. Several studies have shown increased 
amount of special exosome secretion in lung, glioblas-
toma, prostate cancer, ovarian cancer and breast cancer 
cell lines through HIF-1α in hypoxic tumor environment 
[309]. Moreover, it has been shown that hypoxia changed 
the size of exosomes in pancreatic cancer cell lines [310]. 
The capability of exosomes to facilitate intercellular com-
munication and their ability to transport various exog-
enous cargo results in tumor survival, aggressiveness 
angiogenesis and metastasis. Modifying the content and 
biogenesis of exosomes in hypoxic tumor microenvi-
ronment may be an effective therapeutic intervention 
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approach. Biological feature of exosomes, including 
their stability, small size, lack of toxicity, communica-
tion with other cells, slow clearance from circulation and 
cargo loading capacity make them an attractive tool for 
the delivery of therapeutic molecules [309]. An impor-
tant therapeutic intervention strategy may be to alter the 
content and biogenesis of exosomes in a hypoxic tumor 
microenvironnement. The biological characteristics of 
exosomes such as their stability, tiny size, non-toxicity, 
interaction with other cells, slow removal of cargo load-
ing capability and circulation, make them an excellent 
factor for the providing therapeutic molecules [309].
Treatments of cancer emphasize 
microenvironment hypoxia in cancer stem cells
CSCs endowed with stemness and tumorigenic proper-
ties allow tumor development, metastasis and recur-
rence. Conventional anticancer approaches mainly target 
the bulk population of the tumor, whilst sparing CSCs. 
Moreover, surgery-generated hypoxia is also reported 
to result in dedifferentiation of tumor cells into tumor-
initiating stem-like cells [311]. Therefore, a number of 
therapeutic approaches in order to kill CSCs have been 
developed based on altering the microenvironment 
(niches) protecting them.
In this regard, disruption of vasculature, targeting 
metabolism and special pH environment represent as 
alluring landscapes, which can be affected by hypoxia. 
The strategies directed to target VEGF can lead to inter-
rupt the CSC niche. Several studies showed that bevaci-
zumab significantly reduces the GCSCs in glioblastoma 
models [312, 313]. A combination of a VEGFR2 antibody 
with chemotherapy reported by Folkins and coworkers, 
to be more effective against glioma than chemotherapy 
alone [314].
Inhibiting the enzymatic pathways and lactic acid gen-
eration, as the main part of reprogrammed metabolic 
network, also presents promising approaches to CSCs 
elimination. Cui et al. [315], indicated that chronic stress 
via β2-adrenergic receptor upregulated the LDH-A, lead-
ing to a switch to lactate formation, in turn promoted 
stem cell phenotype through USP28/MYC/SLUG axis in 
breast cancer. And that vitamin C reversed the induction 
of stem-like phenotype by inhibition of stress-induced 
LDH-A, and suppressing the lactic acid generation and 
the USP28/MYC/SLUG pathway in BCSCs. Further, 
combining of vitamin C, as inhibitor of glycolysis, with 
the FDA-approved antibiotic doxycycline that reduces 
cellular respiration, reported to be effective for eradicat-
ing CSCs [316].
Mesenchymal CSCs are highly resistant and aggressive 
subpopulation of GCSCs, which can be resisted and even 
upregulated after radiation treatment. This subtype of 
CSCs overexpress ALDH1A3, thus inhibition of ALDH-
mediated pathways could be effective in eradication of 
them [317]. Zhou et al. [318], showed that combining of 
chemotherapy, together with inhibition of glycolysis by 
3-bromopyruvate, effectively eradicates GCSCs in their 
hypoxic niches, where they exhibit resistant to mono-
therapy by chemotherapeutic agents, and tend to reside 
in hypoxia and perform glycolysis for ATP generation 
in order to maintain their stemness and highly tumor 
forming capacity. In addition, in several cancer models, 
inhibition of PDKII by dichloroacetate has been demon-
strated to reverse the metabolic shift from glycolysis to 
OXPHOS, increase ROS and promote apoptosis in CSCs 
and tumor cells [319, 320].
Elimination of the stemness characteristics, such as 
overexpressed drug transporters, considered as the 
major purpose to improve efficacy of chemotherapy. 
The combination therapy consists of inhibitors of HIFα 
or HIF target gene (such as ABC transporters) suggested 
using concomitantly with chemotherapeutic agents. 
For instance, anti-MDR1 siRNA (siMDR1) successfully 
improved the chemo-sensitivity of human colon CSCs 
[321]. Several tyrosine kinase inhibitors such as imatinib, 
erlotinib, nilotinib and lapatinib have been applied to 
inhibit ABC transporters [322]. In addition, various 
strategies based on suppression of transporter function, 
including nanoparticle-mediated delivery of inhibitors, 
competitive and allosteric modulators, regulator of tran-
scriptional and signaling pathways involving ABC trans-
porters have been tested to overcome chemo-resistance 
in CSCs [323], however, none of them has been approved 
yet.
In hypoxiamediated CSC resistance, several signal-
ing pathways recognized to be involved. Therefore, 
these pathways draw much attention as potential tar-
gets to eliminate CSCs, particularly in hypoxic TME. 
Hypoxia promotes Notch and Wnt/β-catenin signaling 
to CSC formation and maintenance, mainly in a HIF-
1α-dependent manner [324]. Targeting Notch4 could 
decrease the number and activity of BCSC in  vivo, as 
well as in vitro [325]. Zhou and coworkers [326], recently 
showed that Notch4 promotes EMT and quiescence in 
mesenchymal BCSC via activation of SLUG and GAS1, 
suggesting Notch4-SLUG-GAS1 serves as a candidate for 
tumor treatment by elimination of mesenchymal BCSC 
stemness and overcoming the lethal form of chemo-
resistant and metastatic triple-negative breast cancer. 
Seo and colleagues [327], further showed that hypoxia-
induced Notch signaling increases self-renewal, drug 
resistance, sphere formation and expression of genes 
relating to CSC features, such as SOX2, ALDH, and ABC 
transporters in ovarian CSCs (OCSCs). In fact, Notch 
signaling mediates the hypoxia-induced expression of 
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Sox2 in a HIF-1 dependent manner, and Sox2 in turn 
upregulates the ABCB1 and ABCG2, thereby promoting 
drug resistance, as well as triggering sphere formation 
and CSCs features. They also showed that the inhibi-
tion of Sox2 in a HIF-1 abrogates hypoxia-induced CSC 
features. Their finding proposed the hypoxia- Notch1-
SOX2 circuit as a potential target to eradicate OCSCs in 
hypoxic condition. Moreover, suppression of MMP-2, 9 
and VEGF abrogates Notch signaling in hepatocellular 
carcinoma cells and decreases tumor invasiveness [328]. 
Hypoxia triggers phenotypic plasticity of CSCs by acti-
vation of Wnt signaling. Yan et  al. [329], also indicated 
that HIF-1α expression increased during acute hypoxia 
(6–12  h), whereas, HIF-2α overexpression continuously 
occurred in chronic hypoxia (48  h) and activated Wnt 
and Notch signaling and expression of stem cell mark-
ers Nanog, c-Myc, and Oct4. Thereby, HIF-2α promoted 
stem phenotype conversion, augmented tumorigenesis 
and induced resistance to chemotherapeutic drug pacli-
taxel. Hypoxia, also, upregulates β-catenin transcription, 
downstream of Wnt, via stabilization of HIF-1α in leu-
kemia CSCs, and promotes their survival [330]. Differ-
ent drugs aimed at inhibiting the Wnt signaling pathway 
have been used to impede this pathway in CSCs [328, 
331]. Evodiamine (Evo), an inhibitor of the Wnt signaling, 
demonstrated that downregulated the expression of Sox2, 
KLF4, Bmi1 and Oct4 in GCCs, thus promoted apoptosis 
and decreased proliferation, sphere formation capacity 
and resistance to oxaliplatin. Evo, also, downregulated 
the expression of Slug, Twist, Zeb1 and vimentin, and 
thereby acquired the inhibitory effect on EMT. Further, 
Evo reduced cMyc, cyclin D1, as well as βcatenin expres-
sion in spheroids from GCCs in gastric cancer [332]. Tri-
fluoperazine is another inhibitor of the Wnt/β-catenin 
pathway with potential anti-CSC properties, which sup-
pressed the CSC marker (CD44/CD133) expression and 
spheroid formation capacity of LCSCs. Combining of this 
inhibitor with gefitinib or cisplatin diminished chemo-
resistance of lung cancer [333]. Natural products have 
been also identified by similar effect. Curcumin inhibits 
β-catenin nuclear localization, hampers the Slug activa-
tion and reverses suppressed E-cadherin expression, sub-
sequently inhibits EMT and migration of BCSCs [334]. 
Cucurbitacin B, inhibitor of Wnt/β-catenin signaling 
derived from pumpkins and guards, inhibits stemness 
and metastasis of non-small cell lung cancer (NSCLC). 
It has also the anti-angiogenic and anti-invasive potential 
against metastatic NSCLC [335].
Hedgehog (Hh) signaling, one of the main pathways 
related to stemness and CSC development, interacts 
with other critical molecular pathways, in particular 
Ras/Raf/MEK/Erk, PI3K/Akt/mTOR and Notch. Hence, 
combined targeting of the component belonged to dif-
ferent signaling pathways result in more effective anti-
cancer strategies [336]. Mitogen-activated protein kinase 
(MAPK)/ERK signaling is one of the key pathways 
exploited by hypoxia to promote CSC phenotype. In 
response to chemotherapy, HIF promotes propagation of 
BCSCs and thereby tumor recurrence. One of the mecha-
nisms proposed is activation of cystine transporter xCT 
and the glutamate-cysteine ligase by HIF-1α that leads to 
increased intracellular glutathione, which in turn inhibits 
mitogen-activated protein kinase MEK activity. Loss of 
MEK-ERK signaling causes FoxO3-mediated transcrip-
tional activation of Nanog, a pluripotency factor required 
for propagation of BCSCs. Targeting this HIF-1-regu-
lated pathway might inhibit the BCSC enrichment and 
tumor relapse after chemotherapy [337].
PI3K/Akt signaling is the other important pathway 
mediating CSC resistance. It is indicated that ERK1/2 and 
PI3K/Akt pathways act at downstream HIF-1α signaling 
in response of GCSCs to hypoxia, and that inhibition of 
these pathways abrogate propagation of CD133-express-
ing GCSCs [73]. Recent finding implicated Akt/Notch1 
signaling cascade as promoter of stemness and pancreatic 
CSCs (PCSCs)-associated resistance, which exacerbated 
in collaborate with hypoxia. Blockade of this pathway 
augmented the cytotoxic effect of gemcitabine [338]. In 
hypoxic GCSCs, HIF2-α through activation of Akt and 
Erk1/2 pathways, upregulates prostatic acid phosphatase 
(PAP) to produce adenosine, which binds to adenosine 
receptor A2B, thereby increases proliferation and tumo-
rigenic capacity [339]. Recently, it is demonstrated that 
celastrol, an anti-glioma medicine, downregulated the 
HIF-1α, blocked the PI3K/Akt/mTOR signaling and dis-
rupted angiogenesis and VM formation. [340]. mTOR, a 
downstream mediator in PI3K/AKT pathway, complicat-
edly regulated by HIF-1α signaling and acts as a nutrient/
hypoxia sensor to modulate protein synthesis. Marhold 
et  al. [341], identified that mTOR was deactivated in 
response to HIF1α upregulation, and inhibits prolifera-
tion, but interestingly promotes quiescence and survival 
of PCSCs in the hypoxic niche. Its possible mechanism 
involves the activation of Akt signaling through mTOR/
S6K/IRS-1 feedback loop. This might be an explanation 
for the failure of selective mTOR inhibitors in clinical 
trials. Altogether, given the complex regulation of the 
molecular pathways and their interactions in response to 
HIFs in CSCs, we found that targeting of several signal-
ing molecule of these pathways provides more efficient 
approaches to overcome CSCs-associated resistance in 
hypoxia.
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Conclusion and future prospectus
While hypoxia has been emerged as a key player in allow-
ing tumor survival, dissemination and invasiveness, this 
review summarizes the significance of HIFs in CSC devel-
opment, malignant progression and cancer resistance to 
chemo-, radio- and immuno-therapy. As a result, HIF sta-
bilization in hypoxic tumor cells induces the expression 
of specific target genes encoding proteins that promote 
neo-angiogenesis (VEGF), metabolic changes (glycolytic 
enzymes and glucose transporters), stemness, EMT and 
metastasis (CXCR4, E-cadherin). Further, tumor hypoxia 
is thought to promote the production of cytokines and 
chemokines, which recruit pro-tumor immune cell and 
diminish tumor immune responses. Therefore, better 
understanding of the hypoxia signaling cascade can open 
new windows to design strategies for targeting HIFs and 
management of hypoxic microenvironment, led to (i) 
limit tumor expansion; (ii) sensitize CSCs; and (iii) over-
come tumor resistance and recurrence.
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